Company / R&D Expense
PharmaCyte Biotech, Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$407.4K
FY2025
5-year range
$301.2K / $916.2K
FY2021-FY2025
Trend
-13.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has declined for 3 consecutive years, from $916,249 in FY2022 to $407,431 in FY2025.
Based on SEC 10-K filings.
$407,431 in FY2025 with a 5-year CAGR of -2.4%.
Declined from $690,937 to $407,431 over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -23.7%
- 5-Year CAGR
- -2.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- PharmaCyte Biotech, Inc.'s r&d expense has declined for 3 consecutive years.
- 5-year CAGR of -2.4%, indicating a declining trend.
- In FY2025, r&d expense decreased 13.0% year-over-year.
- Peak r&d expense was recorded in FY2019.
Company context
Key Data Points
- Altman Z-Score 0.20 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $407.4K | -13.0% |
| FY2024 | $468.5K | -32.2% |
| FY2023 | $690.9K | -24.6% |
| FY2022 | $916.2K | +204.2% |
| FY2021 | $301.2K | -34.5% |
| FY2020 | $460.1K | -77.0% |
| FY2019 | $2.0M | +69.0% |
| FY2018 | $1.2M | -16.0% |
| FY2017 | $1.4M | +334.9% |
| FY2016 | $323.5K | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026